Moxifloxacin — Discount Pricing

Other medications in Infections

• Ofloxacin
• Oritavancin
• Oseltamivir
• Penicillin VK
• Polymyxin B
• Pyrazinamide
• Raltegravir
• Rifampin

What Moxifloxacin is approved for (FDA label)

Moxifloxacin is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia (1.1) Skin and Skin Structure Infections: Uncomplicated (1.2) and Complicated (1.3) Complicated Intra-Abdominal Infections (1.4) Plague (1.5) Acute Bacterial Sinusitis (1.6) Acute Bacterial Exacerbation of Chronic Bronchitis (1.7) To reduce the development of drug-resistant bacteria and maintain the effectiveness of moxifloxacin and other antibacterial drugs.

Source: Read the full FDA label on DailyMed. Label effective date: August 17, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Moxifloxacin (FDA label)

WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1) ] , including: Tendinitis and tendon rupture [see Warnings and Precautions (5.2) ] Peripheral neuropathy [see Warnings and Precautions (5.3) ] Central nervous system effects [see Warnings and Precautions (5.4) ] Discontinue moxifloxacin immediately and avoid the use of fluoroquinolones, including moxifloxacin, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5.1) ] . Fluoroquinolones, including moxifloxacin, may exacerbate muscle weakness in patients with myasthenia gravis.

Source: FDA prescribing information (DailyMed). Set ID: 656f582c-ecba-4ec8-9420-9562114d889b. SPL document ID: 59428a91-3a88-2e83-e063-6294a90a3cef. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Moxifloxacin (FDA label)

Tablets: 400 mg moxifloxacin (3.1) 3.1 Moxifloxacin tablets, USP Pink, biconvex, capsule shaped tablets debossed with “CE” on one side and “312” on the other side containing moxifloxacin (equivalent to 436.33 mg moxifloxacin hydrochloride).

Source: FDA prescribing information (DailyMed). Set ID: 656f582c-ecba-4ec8-9420-9562114d889b. SPL document ID: 59428a91-3a88-2e83-e063-6294a90a3cef. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Moxifloxacin (FDA label)

The following serious and otherwise important adverse reactions are discussed in greater detail in the warnings and precautions section of the label: Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects [see Warnings and Precautions ( 5.1 ) ] Tendinitis and Tendon Rupture [see Warnings and Precautions ( 5.2 ) ] Peripheral Neuropathy [see Warnings and Precautions ( 5.3 ) ] Central Nervous System Effects [see Warnings and Precautions ( 5.4 ) ] Exacerbation of Myasthenia Gravis [see Warnings and Precautions ( 5.5 ) ] QT Prolongation [see Warnings and Precautions ( 5.6 ) ] Other Serious and Sometimes Fatal Adverse Reactions [see Warnings and Precautions ( 5.7 ) ] Risk of Aortic Aneurysm and Dissection [ see Warnings and Precautions ( 5.9 ) ] Hypersensitivity Reactions [see Warnings and Precautions ( 5.8 ) ] Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions ( 5.10 ) ] Blood Glucose Disturbances [see Warnings and Precautions ( 5.12 ) ] Photosensitivity/Phototoxicity [see Warnings and Precautions ( 5.13 ) ] Development of Drug Resistant Bacteria [see Warnings and Precautions ( 5.14 ) ] Most common reactions (3% or greater) were nausea, diarrhea, headache, and dizziness. (6) To report SUSPECTED ADVERSE REACTIONS, contact Chartwell RX, LLC at 1-845-232-1683 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to moxifloxacin in 14981 patients in 71 active controlled Phase II–IV clinical trials in different indications [see Indications and Usage (1) ] . The population studied had a mean age of 50 years (approximately 73% of the population was less than 65 years of age), 50% were male, 63% were Caucasian, 12% were Asian and 9% were Black. Patients received moxifloxacin 400 mg once daily oral, intravenous, or sequentially (intravenous followed by oral). Treatment duration was usually 6 to 10 days, and the mean number of days on therapy was 9 days. Discontinuation of moxifloxacin due to adverse reactions occurred in 5% of patients overall, 4% of patients treated with 400 mg PO, 4% with 400 mg intravenous and 8% with sequential therapy 400 mg oral/intravenous. The most common adverse reactions (>0.3%) leading to discontinuation with the 400 mg oral doses were nausea, diarrhea, dizziness, and vomiting.

Source: FDA prescribing information (DailyMed). Set ID: 656f582c-ecba-4ec8-9420-9562114d889b. SPL document ID: 59428a91-3a88-2e83-e063-6294a90a3cef. Label effective date: August 17, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.